Neuros Medical, Willoughby Hills, Ohio, a medical device company developing high-frequency nerve block technology for patients with intractable post-amputation pain, announced the achievement of two milestones in its High-Frequency Nerve Block for Post-Amputation Pain (QUEST) study. In December 2020, an independent data monitoring committee completed the final planned interim safety and futility analysis of 80 subjects at the 90-day primary endpoints. In addition, QUEST enrollment now exceeds 100 subjects, and the study is on track for completion of enrollment in the fall.
QUEST is a 180-subject, randomized, double-blinded, active sham controlled clinical trial that is being conducted under an investigational device exemption designed to assess the safety and effectiveness of the company’s nerve block system.
